NASDAQ: LXEO - Lexeo Therapeutics, Inc.

Yield per half year: -54.65%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Lexeo Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.

more details
It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2023-11-03
ISIN US52886X1072
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.lexeotx.com
Цена ао 3.99
Change price per day: -0.2433% (4.11)
Change price per week: +51.29% (2.71)
Change price per month: +29.75% (3.16)
Change price per 3 month: -39.53% (6.78)
Change price per half year: -54.65% (9.04)
Change price per year: -73.85% (15.68)
Change price per year to date: -32.12% (6.04)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 3.15 5
P/E 0 0
EV/EBITDA -3.72 0
Total: 3.13

Efficiency

Title Value Grade
ROA, % -47.49 0
ROE, % -58.48 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1746 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % 26.25 4
Yield Ebitda, % 1349.35 10
Yield EPS, % 1092.76 10
Total: 8.8
More

Institutions Volume Share, %
Artal Group S.A. 603435 2.26
Citigroup Inc. 91889 0.34
Bank Of New York Mellon Corporation 14110 0.05
Wells Fargo & Company 72 0

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Micro-Cap ETF 0.06431 -13.97 1.54048
iShares Russell 2000 Growth ETF 0.01747 38.04 0.6026
0.0412.041.07



Head Job title Payment Year of birth
Mr. R. Nolan Townsend CEO & Director 864.34k 1981 (44 years)
Dr. Ronald G. Crystal M.D. Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board N/A
Dr. Eric Adler M.D. Chief Medical Officer & Head of Research 623.4k 1974 (51 year)
Dr. Sandi See Tai M.D. Chief Development Officer N/A 1971 (54 years)
Mr. Ryan McHenry VP & Corporate Controller N/A
Ms. Jenny R. Robertson J.D. Chief Business & Legal Officer 617.9k 1975 (50 years)
Mr. Rand Monaghan Vice President of Finance
Dr. Jose Manuel Otero Ph.D. Chief Technical Officer

Address: United States, New York. NY, 345 Park Avenue South - open in Google maps, open in Yandex maps
Website: https://www.lexeotx.com